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Abstract
Background: Variation in the serotonin transporter (5-HTT) gene (SLC6A4) has been shown to influence a wide range of
affective processes. Low 5-HTT gene-expression has also been suggested to increase the risk of chronic pain. Conditioned
pain modulation (CPM) - i.e. ‘pain inhibits pain’ - is impaired in chronic pain states and, reciprocally, aberrations of CPM may
predict the development of chronic pain. Therefore we hypothesized that a common variation in the SLC6A4 is associated
with inter-individual variation in CPM. Forty-five healthy subjects recruited on the basis of tri-allelic 5-HTTLPR genotype,
with inferred high or low 5-HTT-expression, were included in a double-blind study. A submaximal-effort tourniquet test was
used to provide a standardized degree of conditioning ischemic pain. Individualized noxious heat and pressure pain
thresholds (PPTs) were used as subjective test-modalities and the nociceptive flexion reflex (NFR) was used to provide an
objective neurophysiological window into spinal processing.
Results: The low, as compared to the high, 5-HTT-expressing group exhibited significantly reduced CPM-mediated pain
inhibition for PPTs (p=0.02) and heat-pain (p=0.02). The CPM-mediated inhibition of the NFR, gauged by increases in NFR-
threshold, did not differ significantly between groups (p=0.75). Inhibition of PPTs and heat-pain were correlated
(Spearman’s rho=0.35, p=0.02), whereas the NFR-threshold increase was not significantly correlated with degree of
inhibition of these subjectively reported modalities.
Conclusions: Our results demonstrate the involvement of the tri-allelic 5-HTTLPR genotype in explaining clinically relevant
inter-individual differences in pain perception and regulation. Our results also illustrate that shifts in NFR-thresholds do not
necessarily correlate to the modulation of experienced pain. We discuss various possible mechanisms underlying these
findings and suggest a role of regulation of 5-HT receptors along the neuraxis as a function of differential 5-HTT-expression.
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Introduction
Chronic pain poses a major clinical challenge, markedly reducing
quality of life for many individuals as well as imposing a high
socioeconomic burden on society [1,2]. The familial aggregation of
chronic pain syndromes suggests that the risk for developing
pathological pain is strongly influenced by genetics [3,4]. Investiga-
tions into central processes underlying pain perception has provided
evidence for impairments of regulatory systems, e.g. impaired pain-
inhibition, as a potentially important factor in the development of
persistent pain [5]. Therefore, studies aimed at teasing out the genetic
underpinnings underlying such individual differences in pain
regulation may help to identify clinically relevant biomarkers.
Extensive electrophysiological studies in rodents during hetero-
topic noxious conditioning stimulation (HNCS) revealed a potent,
widespread and selective inhibition of wide dynamic range (WDR)
neurons in the dorsal horn and trigeminal nuclei. These mechanisms
were coined ‘diffuse noxious inhibitory controls’ (DNIC) by Le Bars
and colleagues [6,7,8] and rely on descending projections from
neuronswith whole-bodyreceptivefieldsin the subnucleusreticularis
dorsalis (SRD) in the caudal brainstem [9]. It was subsequently
shown that DNIC-like effects induced by thermal conditioning
stimuli are present in humans, i.e. ‘pain inhibits pain’, and that these
could be assessed using the nociceptive flexion reflex (NFR) [10].
Studies of DNIC-like effects in humans also use reports of the
subjective experience, consequently capturing effects of uncertain
neurophysiologicorigin.Ithasthereforerecentlybeenrecommended
that the collective phenomena should be referred to as conditioned
painmodulation(CPM)ratherthan‘DNIC’whenstudiedinhumans
[11]. In this paper we will adopt the new terminology.
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patients with various types of chronic pain, e.g. fibromyalgia [12]
and painful osteoarthritis [13]. Additionally, altered CPM-
responses have been reported in tension-type headache and
migraine [14] as well as in atypical trigeminal neuralgia [15].
Importantly, individual CPM-response has in a prospective design
been tied to the risk of currently healthy individuals developing
chronic postsurgical pain [16].
The initial DNIC-studies in rodents suggested a pivotal role of
descending serotonergic projections. Whereas administration of
the serotonin (5-HT) precursor 5-hydroxytryptophan (5-HTP) led
to a more potent inhibition, the 5-HT receptor antagonist
cinanserin reversed this potentiation [17,18]. A key player in 5-
HT signaling is the 5-HT transporter (5-HTT), terminating the
extracellular effects of 5-HT by sodium-dependent intracellular re-
uptake [19]. Drugs acting on this integral membrane protein have
a place in the pharmacological arsenal used against unrelenting
pain. Although selective serotonin re-uptake inhibitors (SSRIs)
play a limited role in pain treatment, serotonin-noradrenalin re-
uptake inhibitors (SNRIs) and tricyclic antidepressants are
commonly used to treat various forms of chronic pain. The exact
mechanisms dictating whether these classes of drugs are successful
in any particular patient are poorly understood [20]. As both pain
and analgesic responses have large hereditary components [21], a
genetic approach in mechanistic pain studies may both lead to an
increased understanding of the pathogenesis of chronic pain as
well as suggest pharmacogenomic options for improving treat-
ment.
The human 5-HTT is coded for by a single gene (SLC6A4)
residing on the long arm of chromosome 17 [22]. Polymorphisms
in the promoter region of SLC6A4 are some of the most well-
studied sources of variation in psychiatric genetic research [23].
The initial impetus for such studies came from a report in 1996
that a repeat length polymorphism, the so-called 5-HTT linked
polymorphic region (5-HTTLPR), located in the promoter region
of the SLC6A4 affects transcriptional efficiency. The 5-HTTLPR is
a 43 base pair insertion/deletion in a C/G-rich variable number
tandem repeat (VNTR) sequence located in the promoter region,
yielding a long (l) and a short allele (s) [24]. The s-allele is coupled
to a reduced gene-expression, leading to lower densities of 5-HTT
receptors, and has been implicated in a wide variety of anxiety
disorders and depression [25] and also associated with pain states
such as migraine [26] and fibromyalgia [27,28].
The SLC6A4 harbors many other polymorphisms in addition to
the 5-HTTLPR. In the same promoter region, a single nucleotide
polymorphism (rs25531), implying an A to G substitution, has
been further shown to alter the degree of gene expression [29].
The minor G-allele is nearly always in phase with the 5-HTTLPR
l-allele and is suggested to reduce the transcriptional efficacy to
levels similar to the s-allele. When studied jointly the 5-HTTLPR/
rs25531 mini-haplotype is usually referred to as ‘tri-allelic’ 5-
HTTLPR (due to the very low frequency of the fourth allele, SG,
this is often ignored in studies) implying the functional division of
individuals into high (LA/LA), intermediate (LA/LG,S A/LA) or low
(SA/SA,L G/SA) 5-HTT-expression types respectively [30]. Ethnic
differences are reported and allelic frequencies differ within
European populations [31]; tri-allelic frequencies are reported to
be around 43% (SA), 6.5% (LG) and 50% (LA) [30].
The aim of the present study was to assess whether individual
CPM-response is associated with the tri-allelic 5-HTTLPR. Given
the reported findings of lower 5-HTT gene-expression in chronic
pain [27,32], we hypothesized that the low 5-HTT-expressing
group would exhibit a lesser degree of CPM-mediated pain
inhibition. We employed an individually titrated conditioning
stimulus, namely the submaximal effort tourniquet test (SETT)
[33], and applied three different types of test-stimuli. CPM was
thus studied on individually calibrated supra-threshold noxious
heat, pressure pain thresholds (PPTs) and the nociceptive flexion
reflex (NFR). The NFR is an established electrophysiological
measure of spinal nociceptive processing [34,35]. To our
knowledge this is the first study assessing the effects of CPM on
the basis of tri-allelic 5-HTTLPR. Further it is, to the best of our
knowledge, the first report of using the NFR as an ‘objective’
modality together with other, subjective and qualitatively separate,
modalities of test-stimuli within the same CPM-session.
Methods
Participants
A total of 45 healthy volunteers of European descent, pre-
selected on the basis of their tri-allelic 5-HTTLPR genotype, were
included in the study. The low 5-HTT-expressing group (SA/SA,
LG/SA) contained 22 individuals (13 females). The high 5-HTT
group (LA/LA) was comprised of 23 individuals (15 females). See
Table 1. One additional subject initially enrolled was excluded
from further analysis because of reporting current chronic pain
problems during the post-experimental debriefing.
The study was conducted according to the principles expressed
in the Declaration of Helsinki and was approved by the Regional
Ethical Review Board in Stockholm (reference number 2010/716
– 32). All participants gave their written informed consent.
Subjects were paid for their participation.
Subjects were recruited on the basis of tri-allelic 5-HTTLPR
genotype from a pool of approximately 500 individuals. Both the
experimenters and volunteers were blinded for the genotype.
DNA-samples came from volunteers at a variety of institutions, in
the Stockholm area. Individuals in the pool had provided
informed consent for DNA-analysis and agreed to be contacted
for invitations to participate in research projects within the
neurosciences. Subjects in the pool were naı ¨ve to our paradigm
and had not participated in any similar experiments conducted
by our group. To meet the inclusion criteria participants had to
be healthy, non-pregnant, adults without pain problems and not
suffer from any present or previous psychiatric disorder. Subjects
were of European descent. Except for contraceptives, subjects
were not included if they were currently using any pharmaceu-
Table 1. Participants.
N total N female N male Median age Age range
Low 5-HTT-expressing group 22 13 9 25.5 20–52
High 5-HTT-expressing group 23 15 8 25 20–54
Healthy subjects were recruited based on genotype. Both subjects and experimenters were blinded for genotype. The members of the groups did not differ significantly
in age [U=239.5, z=20.31, p=0.76] and women did not differ significantly in their menstrual cycles between groups [x
2(1)=0.001, p=0.98].
doi:10.1371/journal.pone.0018252.t001
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factors were initially assessed by a brief phone interview during
the recruitment process and further confirmed on the day of
testing. The reported experiment was the last in a battery of
much less invasive sensory tests, conducted on the same day in an
identical manner for all recruited subjects (data will be reported
elsewhere). The other experiments consisted of assessing non-
noxious and threshold temperatures against the ventral forearm,
measurements of the acoustic startle reflex and a trial of cognitive
modulation of pain. In the latter noxious heat (,49uC) was
applied to the left ventral forearm, five times for 30 seconds each
time, with an interval of 5 minutes between each stimulation.
Subjects were given a 10 minute break before the start of the
present experiment.
Genotyping
Samples for DNA-extraction were either obtained in the form of
20 ml whole blood or saliva. DNA-extraction from whole blood
was performed as described earlier [36] and from saliva using the
protocol and reagents in the OrageneH kit (DNA Genotek Inc,
Kanata, Canada).
To determine the tri-allelic 5-HTTLPR, PCR-reactions were
carried out in a total volume of 20 ml containing 50 ng of genomic
template, 0.2 nM of each dNTP, 1 mM of each primer (Thermo
Scientific, Ulm, Germany), 0.05 U/ml Quiagen HotStarHPoly-
merase, 1 M Q-solution and 1x Buffer. The forward primer
sequence was 5’-GGCGTTGCCGCTCTGAATGC-3’ and the
reverse 5’-GAGGGACTGAGCTGGACAACCAC-3’. Samples
were amplified (Biorad Tetrade, Hercules, CA,USA), following
an initial denaturation step for 10 min at 94uC, by 32 cycles of
30 s denaturation (95uC), annealing for 30 s (57uC) and elongation
for 30 s (72uC). This was followed by a final elongation step for
5 min at 72uC. The described PCR yields a long (529 bp) and a
short (486 bp) fragment which were visualized with UV after 2 h
separation at 180 V on a 2.5% agarose gel containing GelRedH.
Additionally, 10 ml of the PCR product were digested for 12 h at
37uC with 0.1 ml MSP1 (New England Biolabs, Ipswitch, MA,
USA) and 1 ml buffer per sample. The MSP1 cuts at a 5’-C/CGG-
3’ sequence. This results in fragments of different length from
which the tri-allelic 5-HTTLPR genotype can be determined. LA
results in 340 bp, 127 bp and 62 bp; S A results in 297 bp, 127 bp,
and 62 bp; L g results in 174 bp, 166 bp, 127 and 62 bp; S g (very
uncommon) results in 166 bp, 131 bp,127 bp and 62 bp. Samples
with the thus digested fragments were visualized using UV-light
after being run for 2 h at 180 V on 4% agarose gels containing
GelRedH
Using the available samples we thus unambiguously genotyped
94% (=call-rate) of the individuals (478 of 511) in our database.
The genotyped individuals in the database did not differ
significantly from Hardy-Weinberg equilibrium (HWE) with
regard to the bi-allelic 5-HTTLPR [x
2(1)=2.9, p=0.1] or the
rs25531 [x
2(1)=1.5, p=0.2], used to construct the tri-allelic 5-
HTTLPR. As mentioned, subjects included in the actual
experiment were selected on the basis of this genotype, rendering
any HWE-calculations for the distribution in the present study
irrelevant.
Questionnaires and scales
Prior to testing, subjects completed the state-part of a Swedish
version of the State Trait Anxiety Inventory (STAI) - question-
naire. After the main experiment, subjects completed the trait-part
of the STAI as well as a Swedish version of Beck Depression
Inventory (BDI). To increase the participants feeling of integrity,
they were provided with envelopes for the questionnaires. If any
part of a questionnaire was left blank, multiple answers were
chosen or answers marked ambiguously, the questionnaire was
excluded from analysis.
One-hundred millimeter long visual analog scales (VAS) were
used for assessment of heat-pain. The left hand side was labeled
‘no pain’ and the right hand side ‘worst pain imaginable.’ Scales
were printed on separate sheets of paper, a new one used for each
rating. For verbal ratings of ischemic pain a Borg CR10 scale was
used [37]. This ties standardized descriptors to corresponding
numerical ratings ranging from 0 to 11 (‘worst possible pain’).
Experimental protocol, an overview
All testing was conducted during daytime to mitigate the
influence of circadian factors on pain perception. Testing was
performed by the same lead and assistant experimenters and
subjects were given ritualized instructions. Upon arrival at the
experimental facility, volunteers provided written informed
consent.
Subject sat comfortably upright in a 3-sectioned clinical
examination bed and the individual temperature to be used for
heat-pain testing was calibrated. Electrodes for NFR-measure-
ments were fitted on the right foot and leg and an uninflated
blood- pressure tourniquet placed around the upper left arm.
Firstly, a baseline reading of pressure pain threshold (PPT) was
assessed using algometry at the right masseter muscle. Secondly,
baseline VAS-ratings were obtained during a 30-second long heat-
stimulus. An individualized level of noxious heat was applied to the
skin overlying the right quadriceps muscle and VAS-ratings were
provided halfway through (i.e. 15 seconds) and at the end of the
stimulus (i.e. 30 seconds). Thirdly, the threshold level of the NFR
was assessed twice. The conditioning stimulus was then induced
using a submaximal-effort tourniquet test (SETT) as described
below and titrated individually to a pain rating of 6 on the Borg
CR10 scale (range 0-11). When the SETT-pain rating had
reached 6 (or 60 grips had been conducted) the CPM-test thus
commenced. To assess conditioned pain modulation (CPM), test-
stimuli were applied in their initial order during the concurrent
ischemic conditioning pain provided by the SETT. The PPT was
assessed immediately at the start of the CPM-test. One minute into
the CPM-test, noxious heat was applied to the right quadriceps
and rated on VAS-scales as during baseline. Two minutes into the
CPM-test, measurement of NFR-threshold started. Subjects also
rated the ischemic pain intensity during the CPM-test at the one
and two minute marks. Details are provided below.
Heat-pain ratings and temperature calibration
A computer controlled Peltier-type thermode with a
30 mm630 mm surface was used for all thermal testing
(PATHWAY model ATS, Medoc, Israel). An initial calibration
was performed to individualize the temperature to be used for the
heat-pain test-stimulus. Whereas the skin overlying the right
quadriceps was used for actual CPM-testing, the right ventral
forearm arm was used for this calibration in order to avoid
sensitization of the leg. A total of six 15 second stimuli, with an
end-to-onset interstimulus interval of 30 seconds, were applied
starting from a baseline of 32.0uC. Destination and return rates
were set at 10.0uC/s. Temperatures of 46.0uC, 47.0uC and
48.0uC, with two trials of each, were applied in a counterbalanced
and double-blinded order. VAS-ratings in mm, provided as soon
as the temperature dropped back to baseline, were entered into a
linear regression to determine the temperature corresponding to
approximately a 60 mm VAS-rating. For safety reasons, the
maximum temperature was set to 48.9uC.
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The PPT is defined as the lowest pressure (measured in kPa)
that, using standardized testing conditions, needs to be applied in
order to cause the slightest sensation of pain. It is a reliable and
widely used measure [38]. PPTs were measured with an algometer
(Somedic Sales AB, Ho ¨rby, Sweden) fitted with a 1 cm
2 pressure
probe and calibrated using a manufacturer-supplied weight
corresponding to 100 kPa. Algometry was performed over the
belly of the right masseter muscle with an approximate rate of
pressure increase of 50 kPa/s. To acquaint subjects with the
procedure and improve their accuracy on reporting the ‘slightest
pain’ by means of pressing a button, an initial trial was conducted
accompanied with verbal instructions. This was immediately
followed by the real test. Testing during conditioning SETT-
induced pain was identical.
Baseline heat-pain
The individualized temperature for noxious heat was applied to
the skin overlying the right quadriceps femoris muscle, approx-
imately 5 cm proximal to the patella. The temperature was
applied for 30 seconds using the experimenter-held thermode.
From a baseline of 32.0uC the temperature increased with
10.0uC/s. Pain was rated at 15 seconds and at the end of the
stimulus. Testing during conditioning SETT-induced pain was
identical.
NFR-threshold determination
Apparatus and NFR-thresholding program. The skin
overlying the right sural nerve was cleaned and abraded using
prepping-paper (3M Red Dot Trace, Cephalon, Nørresundby,
Denmark). A disposable dual electrode with 20 mm center-to-
center distance (Viasys nr 019-429400, Cephalon) was placed in
the retromalleolar fossa on the skin overlying the path of the sural
nerve. Before placement approximately 0.1 ml of salt-free
electrode gel (SpectraH 360, Parker Laboratories Inc, Fairfield,
New Jersey, USA) was applied to each of the two foam pads using
a syringe. The dual electrode was connected to snapleads (Viasys
nr 019-424500, Cephalon) with the cathode placed proximally.
The impedance between the attached electrodes was verified to be
less than 10 kOhm using a UFI checktrode model 1089e (UFI,
California, USA).
The right biceps femoris muscle was used for electromyographic
(EMG) measurements and electrodes were placed approximately
10 cm superior to the popliteal fossa and halfway between the
lateral aspect and the midline of the leg. The area was shaved if
needed and thereafter cleaned and abraded using prepping-paper.
Disposable dry foam electrodes (EL509, BIOPAC Systems Inc,
Goleta, California, USA) were filled with salt-free electrode gel
according to the manufacturer’s instructions and juxtapositioned
on the site. An identical electrode for grounding was placed over
the right proximal fibula. Shielded leads were connected to the
biceps femoris electrodes and connected to an EMG unit
(EMG100C and MP150, BIOPAC Systems Inc) with gain set at
5000, 500 Hz low-pass, and 10 Hz high-pass filtering and a
sampling rate of 2 kHz. For stimulation output to the subject, an
optically isolated constant current stimulator was used (STMI-
SOL, BIOPAC Systems Inc). The stimulation curve was fed to the
stimulator using a data acquisition system (USB 6221 M DAQ
Module, National Instruments Corporation, Austin, Texas, USA)
connected to a computer. The stimulation signal was reliably
synchronized to the EMG-signal.
Each shock consisted of a train of 5 identical square wave pulses,
each 1 ms in duration, spaced 3 ms apart. A commonly used
staircase algorithm [39], increasing and decreasing the stimulus
level in steps of 4 mA, 2 mA and finally 1 mA, was implemented
in a MATLAB-program to find the NFR-threshold. The time
between two shock trains was randomized and gave a minimum of
7 seconds and an average of 10 seconds. This inter-stimulus
interval was chosen to minimize the risk of sensitization or
habituation phenomena and at the same time make the total
measurement time short enough to allow testing during the
conditioning pain procedure.
Our program used the detection rule suggested by France and
co-workers based on the interval-mean of the EMG-signal [39,40].
The EMG-signal was rectified and the interval-mean of the
baseline from 0 ms to 65 ms prior to stimulus onset was compared
to the interval-mean of the rectified signal 90 ms to 150 ms after
the last pulse of the shock-train by means of a z-score. This post-
stimulus time window allows assessment of the RIII-component of
the flexion reflex, without contamination of the earlier RII-
component [39]. An NFR was reported to have occurred for
interval mean z-scores .1.4.
The experimenter validated the program’s interpretation (i.e
‘NFR detected’ or ‘no NFR’) using an online graphic display of the
EMG from the timeframe surrounding the last stimulation. In case
of e.g. excessive muscle movement in the pre-stimulus baseline, as
evident in the EMG-signal, the experimenter would consequently
choose to repeat the stimulus at the same current strength.
Otherwise, by default, the program continued to the next stimulus
level as suggested by the algorithm until the threshold had been
calculated.
NFR-threshold measurement. All subjects wore shorts
during testing and were seated comfortably in a 3-sectioned
neurophysiological examination bed (Sjo ¨bloms Sjukva ˚rdsutrustning
AB, O ¨ rnsko ¨ldsvik, Sweden). A cylindrical cushion, with 20 cm
diameter, was placed below the right knee and the leg section
loweredtogivea120uflexionattheknee.Subjectswereinstructedto
sit as relaxed as possible with their eyes open, looking straight ahead.
A few test stimuli of 2 mA, applied to acquaint subjects with the
sensation, were followed by two consecutive baseline threshold
calibrations. In assessing the threshold, subjects were not asked to
rate the pain from the shocks as this could have confounded the
measurement in the light of the evidence of anticipatory effects on
reflex activity [41]; we wanted to use the NFR as a purely
neurophysiologicmeasurement.Measurement ofthe NFR-threshold
during conditioning SETT-induced pain was identical.
Submaximal effort tourniquet test (SETT) and
CPM-testing
Subjects were told that the measurements conducted during
baseline would be repeated during the SETT but were not
informed about the specific purpose of the test or of the expected
results. A blood-pressure tourniquet (TriCUFFH original, AJ
Medical, Stockholm, Sweden) was applied to the bare upper left
arm. After having the baseline values determined for PPT, heat-
pain and NFR-threshold as described above, the SETT com-
menced. Subjects carried out three maximal-effort isometric grip
exercises, using a grip-training device (Jym
TM, Jym Fitness,
Kingswood, Australia), with their left hand. The highest value
was recorded and the device programmed to give emit a beep
whenever more than 50% of this force was applied.
Subjects then elevated their left arm for approximately 2
minutes for partial exsanguination whereupon the blood pressure
cuff was inflated to 250–260 mmHg. To attenuate individual
factors relating to the possibly unpleasant visual stimulus of a
discolored extremity, all subjects were fitted with a green sleeve
over the arm and hand. Using their ischemic arm, subjects then
carried out grip exercises with the Jym
TM device, releasing the
Conditioned Pain Modulation Associated with SERT
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(indicated by a beep). Grips were synchronized with a metronome
and conducted at 3 second intervals. Every 5 grips participants
verbally rated the arm pain with numbers chosen from a Borg
CR10 scale until a level of 6 or above was reached or until a total
of 60 grip-exercises had been performed, whichever came first.
This marked the start of the CPM-testing, during which the
tourniquet remained inflated between 250 mmHg and
260 mmHg. Importantly, subjects were not told beforehand when
the gripping would be suspended.
Statistics
SPSS Statistics 17.0 (SPSS Inc, Chicago, USA) was used for all
analyses. Two-tailed tests were used unless otherwise stated.
P-values,0.05 were considered significant but Bonferroni-adjust-
ed to control for multiple comparisons where stated. Data is
reported as means 61 standard deviation (SD) and graphs as
means with error bars of 61 standard error of the mean (SEM).
To calculate the effects of the conditioning pain modulation
(CPM), individual CPM-scores were calculated. See Figure 1. For
these, the proportion of difference from baseline was used rather
than the raw difference, in order to control for individual variation
in baseline measures. This gives positive CPM-score values for
pain inhibition and negative ones for facilitation, as compared to
the baseline.
Raw data and derived measures were analyzed with Shapiro-
Wilk tests to assess significant deviations from normality.
Independent t-tests were used to analyze differences between
the genotype groups for STAI-data. A paired-sample t-test was
used to validate the effect of the SETT on the NFR-threshold.
Univariate analyses of variance, with genotype and gender as
fixed factors, were used for analyzing PPT CPM-scores, baseline
heat-pain, average baseline NFR-thresholds, NFR-threshold
CPM-scores and the number of grips needed during the SETT-
procedure. Heat-pain VAS-ratings for 46.0uC, 47.0uC and
48.0uC (each applied twice in a counterbalanced order) were
averaged for each temperature for each subject and entered into
a factorial repeated-measures ANOVA, with gender and
genotype as between-subject factors. Greenhouse-Geisser cor-
rected degrees of freedom were used for this ANOVA as the
assumption of sphericity was violated.
Non-parametric tests were used whenever the assumption of
normality was violated. Mann-Whitney U tests (exact) were used
for comparing genotypes for age, BDI-data, baseline PPTs,
individualized temperatures used for test-stimuli, CPM-scores for
heat- pain, ischemic pain ratings and grip-strength during the
SETT. To assess the potential influence of menstrual cycle,
females were dichotomized by luteal- and follicular-phases. A
Pearson x
2-test was used to check for differences in these
menstrual cycle-phases between genotype groups. Due to the
constrained sample size while only studying females, Mann-
Whitney U tests (exact) were used in assessing the relation between
menstrual cycle-phase and CPM-scores. Wilcoxon signed-rank
tests (exact) were used as a manipulation-check for the effect of the
SETT on PPTs and to test for habituation or sensitization between
15 s and 30 s baseline VAS-ratings for heat-pain.
Results
Questionnaires
For the Beck-depression inventory (BDI), 1 subject’s question-
naire was excluded. Three subjects in each gene group were
excluded for the state-anxiety and a total of 3 were excluded for
the trait-anxiety parts of the STAI-questionnaires. No differences
between the genotype groups were found for BDI-score [U=228,
z=20.32, p=0.76] or trait-anxiety [t(40)=0.35, p=0.73].
However, the low 5-HTT-expressing group reported a signifi-
cantly [t(37)=2.05, p,0.05] higher state-anxiety (mean 31.566.9)
compared to the high 5-HTT-expressing group (mean 27.565.3).
Pressure pain thresholds (PPTs): baseline and during
SETT-pain
Genotype did not have a significant effect on the baseline PPTs
[U=247, z=20.14, p=0.90]. See Figure 2 A. As expected, men
had significantly higher PPTs than women [U=96.5, z=23.31,
p,0.001]. All subjects followed through with the PPT-testing
during the SETT. A manipulation check for PPTs at baseline
compared to those obtained during CPM-testing was significant
Figure 1. Conditioned pain modulation scores (CPM-scores). To control for individual variation with regard to baseline values, the proportion
of difference from baseline was used rather than the difference of raw values. This was done to control for individual variation in baseline measures
and gives positive CPM-scores for pain inhibition and negative ones for facilitation, as compared to the baseline. To enable a comparison of VAS-
ratings with threshold values, we define our CPM-scores as q(b–c)/b where b=baseline value (in kPA, mm or mA) and c= value during CPM. q=1 for
heat-pain VAS-ratings and q=21 for thresholds ratings.
doi:10.1371/journal.pone.0018252.g001
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pain as expected. A significant main effect of tri-allelic 5-
HTTLPR-genotype on PPT CPM-score was found [F(1,41)=
5.99, p=0.02] such that the low 5-HTT-expressing group did not
increase their individually normalized PPTs as much as the high-
expressing group. In other words, the low 5-HTT-expressing
group displayed reduced CPM-scores (0.1160.27) for PPT when
compared to the high 5-HTT-expressing group (0.2860.29). See
Figure 3. No effect of gender [F,1] or gender by genotype
interactions [F(1,41)=2.80, p=0.101] were found. No effect of
menstrual-cycle phase was found [U=92, z=20.25, p=0.8].
Heat-pain: ratings of suprathreshold noxious heat
The measurements obtained during the calibration exhibited
the expected significant main effect of the temperature level on
VAS- ratings [F(1.60, 65.51)=150.92, p,0.001]. I.e. higher
temperatures implied higher ratings of pain. At any given
temperature, there were no significant differences in VAS -ratings
between genotype groups – despite a tendency at 46.0uC for lower
ratings in the low 5-HTT expressing group [t(39.7)=21.65,
p=0.11 for the average of the two stimuli and t(40.5)= 21.97,
p=0.06 for the first rating only]. However, a significant
interaction between temperature level and genotype on the
VAS-ratings emerged [F(1.60, 65.51)=4.10, p=0.03] such that
the low 5-HTT-expressing group’s VAS-ratings increased signif-
icantly more with increasing temperatures as compared to the high
5-HTT-expressing group. See Figure 4. There was no significant
interaction between gender and temperature on the VAS ratings,
F,1.
Heat-pain: baseline and during SETT-pain
No significant differences were found on the basis of genotype
[U=211, z=20.95, p=0.35] or gender [U=209, z=20.68,
p=0.51] between the temperatures used as test-stimuli. See
Figure 2 B. For the individualized temperature, applied at baseline
to the leg, no significant effect of time point on VAS -rating was
found [z=20.08, p=0.94]. There were no significant differences
between the high- versus low 5-HTT-expressing groups with
regard to baseline heat-pain at 15 or 30 seconds, F,1 for both.
The temperatures were intended to yield a 60 mm VAS-rating at
baseline and achieved this with reasonable precision. The low 5-
HTT-expressing group’s mean VAS-rating at 15 seconds was
46 mm618.3 mm compared to the 5-HTT-expressing group’s
mean rating of 47 mm615.1 mm. The corresponding values at 30
seconds were 45 mm622.0 mm and 47 mm620.0 mm for the
two groups, respectively. The aim of the calibration was not the
exact level of the VAS-ratings, but rather to achieve a
standardized baseline pain perception.
Figure 2. Baseline values for test-pain stimuli. A. Pressure pain thresholds (PPTs) in kPA, assessed by algometry, at baseline. Genotype did not
have a significant effect on the baseline level [U=247, z=20.14, p=0.90]. B. No significant differences were found on the basis of genotype [U=211,
z=20.95, p=0.35] between the individualized temperatures used as test-stimuli. C. Average of the two baseline NFR-threshold measurements in mA.
No significant differences were found between groups, F,1.
doi:10.1371/journal.pone.0018252.g002
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the SETT. Individual heat-pain CPM-scores were calculated for
the 15 and 30 second time points, respectively. To control for the
familywise error due to this multiple testing, a p,0.025 was
considered significant. At the 15 second time point genotype
groups did not differ significantly, but exhibited a trend
[U=172.0, z=21.84, p=0.07]. At the 30 sec time point,
however, the high (score=0.4160.34) and low (score=
20.1860.96) 5-HTT-expressing group differed significantly in
their CPM-scores, [U=145.5, z=22.44, p=0.015, r=20.36].
Figure 3. Conditioned pain modulation. The low 5-HTT-expressing group, as compared with the high 5-HTT group, had a significantly
diminished conditioned pain modulation with regard to pressure pain thresholds [F(1,41)=5.99, p=0.02] and heat at 30 seconds [U=145.5,
z=22.44, p=0.02, r=20.36]. There were no significant differences between groups with regard to tonic pain-mediated increase in the threshold for
the nociceptive flexion reflex (NFR), F,1.
doi:10.1371/journal.pone.0018252.g003
Figure 4. Interaction between pain-ratings for suprathreshold noxious heat and genotype. Mean VAS-ratings for suprathreshold noxious
heat, applied to the right ventral forearm, are shown for the low 5-HTT-expressing and high 5-HTT-expressing genotype groups, respectively. The
interaction between temperature level and genotype on the VAS-rating was significant [F(1.60, 65.51)=4.10, p=0.03].
doi:10.1371/journal.pone.0018252.g004
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measurement at 15 seconds [U=62, z=21.6, p=0.1] or at 30
seconds [U=84, z=20.6, p=0.6]. In the low 5-HTT-expressing
group 7 individuals (3 women, 4 men) actually exhibited negative
CPM (i.e. hyperalgesia) at 30 seconds compared to only 2 subjects
in the high expressing group (one of each gender). Dichotomizing
the 30 sec heat-pain data into negative versus positive CPM
showed a non-significant trend with the low-expressing genotype
group being more frequent in the negative CPM group [p=0.07,
Fisher’s exact test].
Nociceptive flexion reflex
Number and timing of shocks. Across all trials, the average
time between two shocks was 10 seconds (range 7 s–16 s). The
number of shocks required for a threshold measurement ranged
between 7 and 32 (mean=13.864.6).
Baseline NFR-threshold values. Two consecutive baseline
NFR-threshold measurements were conducted for each subject
and the two threshold values were averaged for each individual.
No significant differences for this average baseline NFR-threshold
were found on the basis of genotype or gender, F,1 for both. See
Figure 2 C.
NFR-threshold during the SETT-pain. Two subjects in the
low 5-HTT-expressing group (one of each gender) interrupted the
CPM-testing, due to the ischemic SETT-pain, before assessing the
NFR- threshold. One additional male in the low 5-HTT-
expressing group did not complete NFR-testing during the
SETT, due to technical difficulties. All subjects in the high 5-
HTT-expressing group completed the testing. The NFR-threshold
rose significantly during the SETT [t(41)= 22.03, p,0.05]. The
average baseline threshold of 8.5 mA64.7 mA rose during the
ischemic pain to 9.2 mA65.2 mA. No significant differences of
CPM-scores with regard to gender, genotype or their interaction
were found, F,1 for all. No effect of menstrual-cycle phase was
found [U=79, z=20.54, p=0.6]. See Figure 3.
Correlations between CPM-scores for different modalities
The CPM-scores for PPTs displayed a high degree of
correlation with the CPM-scores for heat-pain at 30 seconds
[Spearman’s rho=0.35, p=0.02], a correlation that remained
significant even after controlling for genotype [partial Spearman’s
rho=0.28, p=0.03, one-tailed test]. However, neither values were
significantly correlated with the CPM-scores of the NFR-
thresholds [Spearman’s rho=20.17, p=0.27 for heat and
rho=0.03, p=0.85 for PPT].
Submaximal effort tourniquet test (SETT) parameters
Number of grips and grip-strength. Three subjects in each
genotype group completed the maximum number of 60 grips (2
women and 1 male in each group). Number of grips needed
ranged between 10 and 60 (median=40). Genotype groups did
not differ significantly in grip-strength [U=242.5, z=20.24,
p=0.82] or with regard to the number of grips needed, F,1.
Ischemic pain ratings during SETT. At the onset of CPM-
testing during the SETT (i.e. at first verbal Borg-rating of 6 or
above, or after the completion of 60-grips) the difference between
genotype groups with regard to verbal ratings of ischemic pain was
not significant [U=189.5, z=21.71, p=0.08]. The mean of the
two integer ratings for the ischemic pain obtained during CPM-
testing was calculated for each subject. The low 5-HTT-expressing
group exhibited a significantly higher mean for these pain ratings
(7.761.0) as compared to the high-expressing group (6.961.9)
[U=167.5, z=21.97, p,0.05].
Potential influence of age on CPM
There may be some reason to believe that descending inhibition
may deteriorate at or after middle-age [42].Genotype groups did
not differ significantly in age and the majority of our subjects were
in their twenties. See Table 1. It should therefore be noted that we
have very limited statistical power (skewed age distribution with a
high density around 25 years) to detect any such age-related CPM-
variation. As an exploration, we calculated non-parametric
correlations between age and our CPM-scores. No significant
correlations emerged [rho for age vs PPT=20.17, p=0.26; rho
for heat-pain at 15 s=0.05, p=0.73; rho for heat-pain at
30 s=0.02, p=0.9; rho for NFR=0.11, p=0.48].
Discussion
Our main finding was that conditioned pain modulation (CPM)
diverged on the basis of tri-allelic 5-HTTLPR in healthy
individuals. Based on the SLC6A4 gene’s putative involvement in
chronic pain states such as fibromyalgia [28] and the fact that such
conditions may be accompanied by experimental deficits in pain
regulation [12] we hypothesized that the gene would also be
associated with CPM-response in healthy individuals. We
demonstrate a strong effect of genotype. The low 5-HTT-
expressing group, as compared to high 5-HTT-expressing,
experienced a significantly lower degree of CPM-mediated
inhibition of pressure- and heat-pain sensitivity. The NFR-
thresholds increased significantly during the application of tonic
ischemic pain, indicating the presence of the expected CPM-
mediated inhibitory effect on spinal nocifensive reflexes. Interest-
ingly, however, there were no significant differences between the
genotype groups with regard to this modulation.
Our findings are at variance with a recent study that failed to
find a relationship between the 5-HTTLPR and CPM [43]. The
discrepancy may be explained by differences in statistical power as
well as methodologies. Potvin et al stratified for the bi-allelic 5-
HTTLPR, without additionally considering the rs25531. There is
good evidence that the mini-haplotype (5-HTTLPR, rs22531)
confers additional resolution to a study as the G-allele, on the 5-
HTTLPR l-allele background, reduces the transcriptional efficacy
to the level of the short-allele [44]. A perhaps more important
factor, however, in explaining the discordant findings is the
sensitivity of the actual CPM-paradigm. A review recently
concluded that the application of test-stimuli in parallel with the
conditioning pain, as in our study, yields higher CPM-mediated
inhibition compared to sequential paradigms [45] as used by
Potvin et al. Nonetheless, Potvin and colleagues did successfully
replicate previous results [12] showing an impaired pain
modulation in fibromyalgia patients.
It has been suggested that the degree of pain experienced due to
the conditioning stimulus may be positively correlated to the
degree of pain inhibition through CPM [10]. This supports our
conclusion that the observed differences represent a substantive
finding since the low 5-HTT-expressing group experienced a
significantly reduced CPM-response despite reporting a signifi-
cantly higher level of ischemic pain during the SETT, compared
to the high 5-HTT-expressing group. Interestingly, a reduced
tolerance to ischemic pain has been reported in depressed
individuals [46,47]. Although our subjects were healthy and
non-depressed, low 5-HTT-expression is a known risk-factor for
depression [48] and our results may hence hint at a potential role
of 5-HTT-related mechanisms in ischemic pain-sensitivity.
A possible interpretation of our finding may be that it represents
a relative shift along the balance between nociceptive inhibition
and facilitation, both engaged during tonic ischemic muscle pain,
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pain in myalgia and fibromyalgia patients reduces descending pain
inhibition during physical activity, stressing the clinical relevance
of these mechanisms [49]. Similarly, in healthy individuals,
experimental muscle pain has been shown to impair descending
inhibition when applied together with a cold-pressor test [50]. In
our experiment, peripheral differences in 5-HT metabolism may
have influenced such pro-nociceptive facilitation during the
ischemia. The 5-HTT regulates serotonin plasma levels through
uptake into platelets [51] with higher transporter expression
implying lower levels of serotonin in the blood [52]. Peripheral 5-
HT receptors have been implicated in muscle pain. Accordingly,
intramuscular injections of, granisetron, a 5-HT3 receptor
antagonist, have been shown to reduce experimental muscle pain
[53].
Interestingly, our baseline calibration of suprathreshold heat-
pain temperatures revealed an interaction between genotype and
pain rating. The low 5-HTT-expressing group’s pain ratings
increased significantly more than the high 5-HTT-expressing
group with increasing temperature. Taken together with the
results for the CPM-test, this may imply that either increasing the
stimulus intensity or adding a concomitant tonic pain might
induce pro-nociceptive facilitation in the low 5-HTT-expressing
group.
In the initial electrophysiological reports of DNIC-phenomena
in rodents, Le Bars and colleagues contend that ‘‘DNIC seems to
be to a great extent dependent on the integrity of the descending
serotonergic system.’’ [8]. Pharmacological studies point towards
the same conclusion [17,54]. Resembling the work done on animal
models, the presence of CPM in humans was initially investigated
using the nociceptive flexion reflex (NFR). It was found that the
threshold for the reflex was linked to the subjective report of pain
elicited by the NFR-testing itself, and that the threshold of both
increased after heterotopically applying a conditioning pain
[10,55].
The NFR has been used in many clinical studies and employed
as a research tool for studies of acute and chronic pain [34]. As
expected, we found a significant upward shift in NFR-thresholds
during tonic pain, but without any differences between the groups.
Whereas the CPM-score for the reported pain experience of
pressure and heat- pain where strongly correlated, there was not
even a tendency for correlation between the shifts in ratings of
subjective pain and the shift in NFR-threshold. Comparing
different reports, the ‘subjective studies’ and ‘objective studies’
seem to show equal effect sizes [45]. To the best of our knowledge,
though, this is the first report of CPM-effects determined
simultaneously for NFR along with other test-modalities in the
same subjects. Importantly, however, it is not the first time
subjective pain reports have been decoupled from the NFR-
response [56,57,58].
With a CPM related to different levels of inferred 5-HTT-
expression, we have the opportunity to compare reported pain
experience with a neurophysiological measurement of spinal
nocifensive processing in relation to serotonin metabolism.
Obviously pain perception is highly dependent on cortical
mechanisms. As mentioned, we found a decoupling of the CPM-
score for spinal nocifensive reflex activity from CPM-scores based
on subjective pain report. Neuroreceptor imaging in healthy
human subjects has shown an increase in selective binding to
supraspinal 5-HTT in subjects homozygous for the LA allele [59].
In the field of affective regulation, numerous differences have been
found with regard to the 5-HTTLPR [23]. The low 5-HTT-
expressing group reported a slight but significant higher state-
anxiety compared to the high-expressing group. Such differences
may have altered the capacity to recruit descending inhibitory
systems during tonic pain as well as influenced the cortical
processing of the pain percepts per se.
Another possible interpretation of the decoupling between
NFR-thresholds and subjective pain during CPM is that, whereas
flexor responses appear to rely on wide-dynamic range (WDR)
neurons in deeper lamina (e.g. lamina V) [60], the actual
perception of heat and pressure pain intensity may depend more
on afferent activity reaching nociceptive specific (NS) neurons in
lamina I [61]. Lamina I neurons are known to project to areas of
the insular cortex [62], an important interoceptive area, the
functioning of which, in turn, has been demonstrated to be directly
affected by SSRIs [63].
The NFR is part of a spinal network of interneurons onto which
many so-called flexor-reflex-afferents (FRAs) of varied, but mainly
non-nociceptive, peripheral origin synapse [35]. Despite the
evidence for the important role of 5-HT in DNIC-effects observed
in deeper WDR neurons, and the complex interplay between
WDR and NS neurons [64], there is nothing that would rule out
differential serotonergic modulation of lamina I neurons. Although
deeper lamina are rich in 5-HT fibers, lamina I and II are the
most abundant in varicosities [65] and 5-HTT has been shown to
co-localize with such varicosities in the spinal cord [66]. Also,
lamina I neurons are almost unique in receiving direct projections
from the hypothalamus which have been shown to produce
antinociceptive effects mediated through 5-HT1A, 5-HT1B and 5-
HT3 receptors [61,67]. The superficial laminae are also densely
innervated by descending serotonergic neurons from the rostro-
ventral medulla (RVM) from which certain neuronal populations-
illustrating the complexity of spinal nociceptive processing – have
a facilitatory role. It should however be emphasized that such
facilitation may be more involved in the development of persistent
pain rather than in the perception of acute pain [68].
The individual classes of serotonin receptors exhibit a myriad of
reported interactions. For example, the superficial laminae of the
dorsal horn are rich in 5-HT1A receptors which can partake in
both inhibitory and facilitory processes [69]. The density of
receptors is dynamic and 5-HTT knockout models illustrate the
compensatory up-regulation (of e.g. 5-HT3) as well as functional
down- regulation of others (e.g. 5-HT1A) [70]. We recently
reported that low 5-HTT-expressing individuals experience
greater pain relief than high 5-HTT-expressing individuals after
an injection of the short-acting opioid remifentanil and suggested
how this may be linked to a desensitization of 5-HT1A receptors
[71]. While 5-HT1A receptor agonists may promote pronocicep-
tion at baseline, possibly explaining the observed interaction
between genotype and suprathreshold heat-pain ratings, 5-HT1A
receptor activation promotes analgesia during concurrent tonic
pain stimulation[72,73]. This would seem to fit well with our
current results, with putatively down-regulated 5-HT1A receptors
in the low 5-HTT-expressing group which indeed exhibited a
reduced pain inhibition during tonic pain.
It is likely that a number of the discussed mechanisms are at
play in the demonstrated genotypic differences. Our study had
several limitations and conclusions drawn from studies using
evoked pain of short duration in healthy volunteers cannot
necessarily be extrapolated to the clinical setting. 5-HTT
expression was inferred from genotype rather than measured
directly and, as in all genetic-associations studies, causality cannot
be asserted. For further interpretation, our findings need to be
replicated for larger samples of individuals in studies aimed at
teasing apart the involved mechanisms. As the ability to inhibit
pain through CPM has been prospectively tied to risk of
developing chronic post-surgical pain [16], it would therefore be
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HTTLPR on the chronification of acute pain. This could
potentially help to identify individuals at risk and, if coupled to a
greater mechanistic understanding of the underlying pain
processes, may direct preemptive pharmacological treatment.
In sum, our results demonstrate the involvement of the SLC6A4
gene in explaining aspects of clinically relevant individual
differences in pain perception and regulation. The tri-allelic 5-
HTTLPR appears to be associated with healthy European adults’
capacity to recruit pain modulatory systems in an experimental
setting of acute tonic ischemic pain. Furthermore, our results
illustrate that shifts in NFR-thresholds do not necessarily correlate
to the modulation of experienced pain. The differences in reported
pain experience may represent a shift in the balance between
inhibition and facilitation, towards the latter, in the group with low
5-HTT-expression. Additionally, cortical factors related to the
pain perception per se may have differed between groups, as
perhaps suggested by the differences in anxiety levels. The
involved mechanisms may be related to the putative up/down -
regulation of various receptors, e.g. 5-HT1A, along different levels
of the neuraxis as a function of differential 5-HTT expression.
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